KURA vs. SUPN, TARO, SYRE, RCUS, EWTX, LGND, GPCR, SDGR, HRMY, and AVDL
Should you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Supernus Pharmaceuticals (SUPN), Taro Pharmaceutical Industries (TARO), Spyre Therapeutics (SYRE), Arcus Biosciences (RCUS), Edgewise Therapeutics (EWTX), Ligand Pharmaceuticals (LGND), Structure Therapeutics (GPCR), Schrödinger (SDGR), Harmony Biosciences (HRMY), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical preparations" industry.
Supernus Pharmaceuticals (NASDAQ:SUPN) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.
Supernus Pharmaceuticals presently has a consensus target price of $41.00, indicating a potential upside of 41.43%. Kura Oncology has a consensus target price of $27.94, indicating a potential upside of 23.07%. Given Kura Oncology's stronger consensus rating and higher probable upside, research analysts plainly believe Supernus Pharmaceuticals is more favorable than Kura Oncology.
Supernus Pharmaceuticals has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.
Kura Oncology has a net margin of 0.00% compared to Kura Oncology's net margin of -2.60%. Kura Oncology's return on equity of -1.68% beat Supernus Pharmaceuticals' return on equity.
Supernus Pharmaceuticals received 68 more outperform votes than Kura Oncology when rated by MarketBeat users. Likewise, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 69.01% of users gave Kura Oncology an outperform vote.
Supernus Pharmaceuticals has higher revenue and earnings than Kura Oncology. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kura Oncology had 5 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 10 mentions for Kura Oncology and 5 mentions for Supernus Pharmaceuticals. Kura Oncology's average media sentiment score of 0.80 beat Supernus Pharmaceuticals' score of 0.49 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.
Summary
Supernus Pharmaceuticals beats Kura Oncology on 11 of the 15 factors compared between the two stocks.
Get Kura Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kura Oncology Competitors List
Related Companies and Tools
